- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00203307
A Research Study Examining the Use of Olanzapine for the Prevention of Migraine
A Single-Site, Double-Blind, Placebo-Controlled Cross-Over Trial Examining the Safety and Efficacy of Olanzapine Taken Daily for the Prevention of Episodic Migraine.
Olanzapine (o-lan-zah-peen) is a medication that has been approved by the Food and Drug Administration (FDA) for the treatment of patients with schizophrenia and/ or bipolar disorder. The trade name for this drug is Zyprexa®. Olanzapine has not been approved by the FDA for the prevention of migraine and is experimental for the purposes of this research study.
The Jefferson Headache Center at Thomas Jefferson University has developed this clinical study to evaluate the safety and effectiveness of Olanzapine in preventing migraine headaches.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Jefferson Headache Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects who are male or female between the ages of 18 and 65, inclusive
- Subjects who have a history of migraine with or without aura as defined by IHS criteria, for at least one year prior to screening
- Subjects who experience between 3 and 10 migraine attacks per month, for the three months preceding screening
- Subjects who have no more than 15 headache days per month
- Subjects who have been on a stable dose (no clinically significant changes) of all daily medications, for any indication, from 28 days prior to screening through the duration of the trial.
- Women who are using, or agree to use for the duration of the study, a medically acceptable form of contraception (as determined by the investigator), if female of childbearing potential.
- Subjects who are able to understand and comply with all study requirements
- Subjects who provide written informed consent prior to any study procedures being performed.
Exclusion Criteria:
- Women who are pregnant or lactating
- Subjects with an abnormal ECG that, in the investigators opinion, would expose them to increased risk of adverse events or interfere with study drug and/or analysis of efficacy/tolerability (subjects with QTC interval greater than 450ms will be excluded)
- Subjects currently taking, or have taken within the thirty days prior to screening, any neuroleptics > 1 day per week (such as Geodon, Zyprexa, Compazine, Phenergan, Seroquel and other drugs in the same class)
- Subjects currently taking or have taken within 4-weeks prior to screening any medication for the prevention of migraine
- Subjects who have failed more than two adequate trials of migraine prophylaxis, as determined by investigator
- Subjects who experience significant orthostatic hypotension, as determined by the investigator
- Subjects who, in the investigators opinion, have a history or have evidence of a medical condition that would expose them to an increased risk of a significant adverse event or would interfere with the assessments of efficacy and tolerability during this trial
- Subjects who, in the investigators opinion, have a history or have evidence of a psychiatric condition that would expose them to an increased risk of a significant adverse event or would interfere with the assessments of efficacy and tolerability during this trial.
- Subjects who have participated in an investigational drug trial in the 30 days prior to the screening visit
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Olanzapine then Placebo
Olazepam
|
Olanzapine (5-10 mg) daily during first intervention period, then placebo(matching)druing second intervention period (after a washout period)
|
Other: Placebo then olanzapine
|
Placebo (matching) during first intervention period, then olanzapine (5-10 mg.
daily) during the second intervention period (after a washout phase).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference in Migraine Headache Periods During the Active Treatment Period as Compared to the Placebo Treatment Period, Per Subject.
Time Frame: 84 day period on placebo compared to 84 day period on olanzapine
|
Definition of migraine headache period: One migraine period is defined as a 24-hour period starting at the time of onset of the migraine headache, during which the migraine headache is present*. Definition of time frames: First treatment period: Day 1 to 84. Second treatment period: day 113-196. Washout phase is day 85-112. |
84 day period on placebo compared to 84 day period on olanzapine
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Reduction of Migraine Attack Frequency During Each 28-day Interval of the Active Treatment Period as Compared to Each 28-day Interval of the Placebo Treatment Period, Per Subject. Individual Migraine Attacks Are Separated by 48-hours Pain Free Time. A
Time Frame: each 28 day interval of active treatment c ompared to placebo
|
each 28 day interval of active treatment c ompared to placebo
|
Reduction in Days Using an Acute Headache Treatment During the Active Treatment Period as Compared to the Placebo Treatment Period, Per Subject.
Time Frame: 84 day period on olanzapine compared to 84 day period on placebo
|
84 day period on olanzapine compared to 84 day period on placebo
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Stephen D Silberstein, Thomas Jefferson University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Headache Disorders, Primary
- Headache Disorders
- Migraine Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Antiemetics
- Gastrointestinal Agents
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Olanzapine
Other Study ID Numbers
- SDS/ZYP/02
- 080-19000-H55901
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Migraine
-
Austrian Migraine Registry CollaborationMedical University of Vienna; Medical University Innsbruck; Austrian Headache...RecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineAustria
-
Tonix Pharmaceuticals, Inc.PremierCompletedChronic Migraine | Chronic Migraine, Headache | Chronic Migraine Without Aura | Aura MigraineUnited States
-
Harvard University Faculty of MedicineBrigham and Women's Hospital; Palmer Center for Chiropractic Research (PCCR)CompletedMigraine | Migraine Disorders | Migraine Without Aura | Migraine With Aura | Migraine, ClassicUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
CoolTech LLCTerminatedMigraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
Notre-Dame Hospital, Montreal, Quebec, CanadaAllerganCompletedChronic Migraine | Migraine Without Aura | Migraine With AuraCanada
-
Glostrup University Hospital, CopenhagenUnknownChronic Migraine | Migraine Without Aura | Migraine With AuraDenmark
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...CompletedMigraine With Aura | Migraine in ChildrenItaly
-
The Cleveland ClinicWithdrawnMigraine | Migraine Disorders | Headache Disorders, Primary | Migraine Headache | Migraine Without Aura | Migraine With Aura | Headache, MigraineUnited States
Clinical Trials on Olanzapine during first intervention period and placebo during second intervention period
-
Institut Claudius RegaudCompleted
-
Beth Israel Deaconess Medical CenterHarvard UniversityCompletedAcetaminophen ToxicityUnited States
-
Hospices Civils de LyonCompletedType 2 DiabetesFrance
-
Hospital of South West JutlandNovo Nordisk A/SNot yet recruitingPhysical Activity | Postoperative Pain, Acute | Postoperative Pain, Chronic | Bariatric Surgery | MobilizationDenmark
-
Ailin LuoBeijing Hospital; Renmin Hospital of Wuhan University; Chinese Academy of Medical...RecruitingPeroperative Complication | Perioperative Cardiavascular Complication | Perioperative Pulmonary Complication | Perioperative Neurological ComplicationChina
-
Ankara Training and Research HospitalRecruitingBladder Cancer | Superficial Bladder Cancer | Tumor Recurrence | Epirubicin Adverse ReactionTurkey
-
London School of Hygiene and Tropical MedicineThe Dementia Society of Goa, India; Goa Medical CollegeCompletedBehavioral Symptoms | Dementia | Mental HealthIndia
-
MANA RBMBayer; Tulane University; Barbara Ann Karmanos Cancer Institute; Carolina Urologic...TerminatedMetastatic Castration-resistant Prostate CancerUnited States
-
Olivier HugliUniversity of Lausanne HospitalsCompletedPain, Acute | Catheterization, PeripheralSwitzerland
-
Northwestern UniversityCompleted